| Literature DB >> 33159421 |
Alberta Iacono1, Andrea Pompa2,3, Francesca De Marchis3, Eleonora Panfili1, Francesco A Greco4, Alice Coletti4, Ciriana Orabona1, Claudia Volpi1, Maria L Belladonna1, Giada Mondanelli, Elisa Albini1,4, Carmine Vacca1, Marco Gargaro1, Francesca Fallarino1, Roberta Bianchi1, Carine De Marcos Lousa5,6, Emilia Mc Mazza7, Silvio Bicciato8, Elisa Proietti1, Francesca Milano9, Maria P Martelli9, Ioana M Iamandii1, Mariona Graupera Garcia-Mila10, Judith Llena Sopena10, Phillip Hawkins11, Sabine Suire11, Klaus Okkenhaug12, Anne-Katrien Stark12, Fabio Grassi13, Michele Bellucci3, Paolo Puccetti1, Laura Santambrogio14, Antonio Macchiarulo4, Ursula Grohmann1,15, Maria T Pallotta1.
Abstract
Knowledge of a protein's spatial dynamics at the subcellular level is key to understanding its function(s), interactions, and associated intracellular events. Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytosolic enzyme that controls immune responses via tryptophan metabolism, mainly through its enzymic activity. When phosphorylated, however, IDO1 acts as a signaling molecule in plasmacytoid dendritic cells (pDCs), thus activating genomic effects, ultimately leading to long-lasting immunosuppression. Whether the two activities-namely, the catalytic and signaling functions-are spatially segregated has been unclear. We found that, under conditions favoring signaling rather than catabolic events, IDO1 shifts from the cytosol to early endosomes. The event requires interaction with class IA phosphoinositide 3-kinases (PI3Ks), which become activated, resulting in full expression of the immunoregulatory phenotype in vivo in pDCs as resulting from IDO1-dependent signaling events. Thus, IDO1's spatial dynamics meet the needs for short-acting as well as durable mechanisms of immune suppression, both under acute and chronic inflammatory conditions. These data expand the theoretical basis for an IDO1-centered therapy in inflammation and autoimmunity.Entities:
Keywords: dendritic cells; early endosomes; indoleamine 2,3-dioxygenase 1 (IDO1); phosphoinositide 3-kinase (PI3K); tryptophan metabolism
Mesh:
Substances:
Year: 2020 PMID: 33159421 PMCID: PMC7726814 DOI: 10.15252/embr.201949756
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 9.071